Table 5.

Plasma prightharmacokinetics and tumor accumulation of polymeric paclitaxel micelles and paclitaxel in mouse models.

				AUC (μg·h/mL)
Mice	Bearing	Treatment	Dose (mg/kg)	Tumor	Plasma	Ref.
Female SPF C57BL/6	B16 melanoma	Genexol-PM	50	3714	77	[25]
		Paclitaxel	20	2140	85
Genexol-PM/ Paclitaxel ratio				1.7	0.9
Female CDF1	Colon 26	NK-105	50	3192	7862
		Paclitaxel	50	133	91
NK-105/Paclitaxel ratio				24.0	86.4	[24]
Female CDF1	Colon 26	NK-105	100	7965	15574
		Paclitaxel	100	331	309
NK-105/Paclitaxel ratio				24.1	50.4